COMP <GO>
NEPH vs MRK // RSI-14 & 200D SMA MOMENTUM
Nephros Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: NEPH 3
— MRK 9
▲ RSI-14 & 200D SMA MOMENTUM LEADER: MRK
LAST: $3.27 (+3.16%) • MKT CAP: $35.5M
rsi-technicals
40.5
LAST: $146.33 (+3.83%) • MKT CAP: $361.02B
rsi-technicals
51.7
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NEPH VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NEPH | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 61.90% | 74.80% | -12.90 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.90% | 20.70% | -1.80 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 26.3x | 15.3x | +11.00 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 4.50% | 3.42% | +1.08 | NEPH | /fcf-yield <GO> |
| Operating Margin | 6.10% | 34.30% | -28.20 | MRK | /operating-margins <GO> |
| Net Profit Margin | 6.40% | 28.10% | -21.70 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 32.70% | 1.30% | +31.40 | NEPH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.19 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | NEPH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 40.5 | 51.7 | -11.20 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.0x | 18.4x | +6.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $35.5M | $361.02B | -$360.99B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NEPH REV | MRK REV | NEPH GROSS % | MRK GROSS % | NEPH FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $18.8M | $65.01B | 61.9% | 74.8% | $1.6M | $12.36B |
| FY 2024 | $14.2M | $64.17B | 61.6% | 76.3% | -$547.0K | $18.10B |
| FY 2023 | $14.2M | $60.12B | — | — | $827.0K | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NEPH // BETA —
MRK // BETA 0.92